PubMed-compiled information sheet
This sheet was compiled from PubMed (NIH) abstracts using AI assistance. Every factual claim is cited to a real PubMed article (see the source list). It has not yet been human-reviewed — confirm with a healthcare provider before use.
Compiled from 30 PubMed articles · model: gemma4:31b
Summary
Background
Traditional uses
Active compounds
Mechanism of action
Clinical evidence
Daily supplementation for 6-8 weeks significantly reduces systolic blood pressure [PMID:32794414].
4-week supplementation significantly altered systolic and diastolic blood pressure, heart rate, and decreased LDL levels and cholesterol in specific subgroups [PMID:33666827].
Daily supplementation for 6-8 weeks significantly reduces total cholesterol [PMID:32794414].
Chokeberry extract inhibited LPS- and PA-induced IL-6 mRNA expression in human primary pre-adipocytes [PMID:38644957].
In mice, black chokeberry suppressed uric acid levels and decreased xanthine oxidase activity [PMID:40438343].
Potential for improving glycemia, though effectiveness may be limited by low bioavailability [PMID:37836472].
Safety & adverse effects
Evidence summary
PubMed sources
- 1.PMID: 36431924 (2022) — Potential Benefits of Black Chokeberry (Aronia melanocarpa) Fruits and Their Constituents in Improving Human Health. · Molecules (Basel, Switzerland)
- 2.PMID: 31619015 (2019) — Black Chokeberry Aronia melanocarpa L.-A Qualitative Composition, Phenolic Profile and Antioxidant Potential. · Molecules (Basel, Switzerland)
- 3.PMID: 28590446 (2017) — Fruits of Black Chokeberry Aronia melanocarpa in the Prevention of Chronic Diseases. · Molecules (Basel, Switzerland)
- 4.PMID: 38543024 (2024) — Comprehensive Utilization Technology of Aronia melanocarpa. · Molecules (Basel, Switzerland)
- 5.PMID: 39499790 (2025) — The Effect of Black Chokeberry (Aronia melanocarpa) on Human Inflammation Biomarkers and Antioxidant Enzymes: A Systematic Review of Randomized Controlled Trials.